scholarly journals P14.76 Characteristics of anaplastic oligodendrogliomas short-term survivors: a POLA network study

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii85-iii85
Author(s):  
L Garnier ◽  
C Dehais ◽  
E Curtit ◽  
E Tabouret ◽  
C Ramirez ◽  
...  

Abstract BACKGROUND Although patients with 1p/19q codeleted anaplastic oligodendrogliomas (AO) usually have a prolonged survival, some patients have a poorer outcome. The aim of the present study was to analyze their characteristics. MATERIAL AND METHODS The characteristics of AO patients with a survival < 5 years included in the POLA network were analyzed and compared to those of AO patients with a survival > 5 years. RESULTS In January 2019, among the 519 patients AO patients included in the POLA network, 55 patients were short-term survivors and 146 patients had a survival > 5 years. Among the 55 AO short-term survivors, 44 patients (80%) died from tumor progression and 11 patients (20%) from another cause (suicide n=2, toxicity n=2, intercurrent disease n=6, other n=1). Compared to > 5 years survivors, short-term survivors were older (57 years vs 48 years, p<0.001) and less frequently presented with isolated seizures (9% vs 33%, p=0.0017). They presented with tumors that more frequently involved multiple lobes (66% vs 47%, p=0.03), had a higher rate of nuclear atypia (80% vs 48%, p<0.001), a higher proliferative index (Ki67, 26% vs 18%, p<0.001), a higher level of p53 expression (10.8% vs 3.9% p<0.001), and had a higher rate of chromosomal abnormalities (91% vs 71% p=0.008). Compared to > 5 years survivors, short-term survivors less frequently underwent a surgical resection (64% vs 89% p<0.001) and their initial treatment more frequently consisted in temozolomide chemotherapy alone (41% vs 20% p=0.008). CONCLUSION AO short-term survivors are associated with distinct clinical, radiological, histological and molecular characteristics at diagnosis.

2017 ◽  
Vol 152 (5) ◽  
pp. S576-S577 ◽  
Author(s):  
Nan Lan ◽  
Luca Stocchi ◽  
Jean Ashburn ◽  
Tracy L. Hull ◽  
Conor P. Delaney ◽  
...  

2008 ◽  
Vol 104 (1) ◽  
pp. 133-141 ◽  
Author(s):  
Roel Bakx ◽  
Annemiek Doeksen ◽  
J Frederik M Slors ◽  
Willem A Bemelman ◽  
J Jan B van Lanschot ◽  
...  

Cancer ◽  
2010 ◽  
Vol 116 (23) ◽  
pp. 5391-5399 ◽  
Author(s):  
Claire F. Snyder ◽  
Kevin D. Frick ◽  
Amanda L. Blackford ◽  
Robert J. Herbert ◽  
Bridget A. Neville ◽  
...  

1996 ◽  
Vol 105 (5) ◽  
pp. 604-612 ◽  
Author(s):  
Giovanni Lanza ◽  
Iva Maestri ◽  
Alessandra Dubini ◽  
Roberta Gafa′ ◽  
Alessandra Santini ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1689 ◽  
Author(s):  
Bianca Grosser ◽  
Meike Kohlruss ◽  
Julia Slotta-Huspenina ◽  
Moritz Jesinghaus ◽  
Nicole Pfarr ◽  
...  

We investigated the prognostic and predictive impact of p53 expression for gastric cancer (GC) patients treated without or with preoperative chemotherapy (CTx) and its relationship with specific molecular GC subtypes. Specimens from 694 GC patients (562 surgical resection specimens without or after CTx, 132 biopsies before CTx) were analyzed by p53 immunohistochemistry. High (H) and low (L) microsatellite instability (MSI) and Epstein–Barr virus positivity were determined previously. Our results show that aberrant p53 expression was a negative prognostic factor in uni- and multivariable analysis in the resection specimens cohort (each p < 0.01). Subgroup analysis showed the strongest prognostic effect for patients with distally located tumors or no CTx treatment. In the biopsy cohort before CTx, p53 did not predict response or survival. p53 expression was significantly different among the molecular subtypes in surgical resection and bioptic specimens with strong association of altered p53 with MSI-L. Patients with MSI-H and aberrant p53 showed the worst survival in the biopsy cohort. In conclusion, the prognostic impact of p53 in GC differs according to tumor localization and CTx. Altered p53 is characteristic for MSI-L, and the p53 status in biopsies before CTx delineates MSI-H subtypes with inverse prognostic impact.


Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Daniela Koppold-Liebscher ◽  
Christian S. Kessler ◽  
Nico Steckhan ◽  
Vanessa Bähr ◽  
Cornelia Kempter ◽  
...  

Abstract Background/objectives A few preliminary studies have documented the safety and feasibility of repeated short-term fasting in patients undergoing chemotherapy. However, there is a lack of data from larger randomized trials on the effects of short-term fasting on quality of life, reduction of side effects during chemotherapy, and a possible reduction of tumor progression. Moreover, no data is available on the effectiveness of fasting approaches compared to so-called healthy diets. We aim to investigate whether the potentially beneficial effects of short-term fasting can be confirmed in a larger randomized trial and can compare favorably to a plant-based wholefood diet. Methods This is a multicenter, randomized, controlled, two-armed interventional study with a parallel group assignment. One hundred fifty patients, including 120 breast cancer patients and 30 patients with ovarian cancer, are to be randomized to one of two nutritional interventions accompanying chemotherapy: (1) repeated short-term fasting with a maximum energy supply of 350–400 kcal on fasting days or (2) repeated short-term normocaloric plant-based diet with restriction of refined carbohydrates. The primary outcome is disease-related quality of life, as assessed by the functional assessment of the chronic illness therapy measurement system. Secondary outcomes include changes in the Hospital Anxiety and Depression Score and as well as frequency and severity of chemotherapy-induced side effects based on the Common Terminology Criteria of Adverse Events. Explorative analysis in a subpopulation will compare histological complete remissions in patients with neoadjuvant treatments. Discussion/planned outcomes Preclinical data and a small number of clinical studies suggest that repeated short-term fasting may reduce the side effects of chemotherapy, enhance quality of life, and eventually slow down tumor progression. Experimental research suggests that the effects of fasting may partly be caused by the restriction of animal protein and refined carbohydrates. This study is the first confirmatory, randomized controlled, clinical study, comparing the effects of short-term fasting to a short-term, plant-based, low-sugar diet during chemotherapy on quality of life and histological tumor remission. Trial registration ClinicalTrials.gov NCT03162289. Registered on 22 May 2017


Author(s):  
James Felker ◽  
Brianna Patterson ◽  
David Wrubel ◽  
Anna Janss

Abstract Prolactinomas are a rare subset of brain tumors in pediatrics. We report a child with a prolactin secreting macroadenoma which was refractory to initial treatment with a dopamine antagonist. Given the location of her tumor she was ineligible for surgical resection. Temozolomide (200 mg/m


2010 ◽  
Vol 43 (4) ◽  
pp. 467-468 ◽  
Author(s):  
Felipe Francisco Tuon ◽  
Carolina Pozzi ◽  
Sergio Ricardo Penteado-Filho ◽  
Ricardo Benvenutti ◽  
Fabiana Loss de Carvalho Contieri

Acremonium infection is rare and associated with immunosuppression. A case of recurrent cutaneous Acremonium infection after short term voriconazole use is described. Surgical resection was the definitive therapy. Oral voriconazole was used in the treatment of Acremonium infection, but recurrence was associated with short therapy. Prolonged antifungal therapy and surgical resection are discussed for the treatment of localized lesions.


Sign in / Sign up

Export Citation Format

Share Document